Ra Capital Management, L.P. Sage Therapeutics, Inc. Transaction History

Ra Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $60.6 Million - $70.3 Million	-384,001 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $34.3 Million - $62.8 Million	384,001 New	384,001 $61.1 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $28.8 Million - $49 Million	-350,933 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $308,792 - $386,672	-2,200 Reduced 0.62%	350,933 $54.9 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $15.5 Million - $19.6 Million	-102,040 Reduced 22.42%	353,133 $56.9 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $27.6 Million - $76.2 Million	455,173	455,173 $75 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.